before that was followed by a progressive insomnia, also associated with behavioral and mood lability.
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Monitoring Subthalamic Oscillations for 24 Hours in a Freely Moving Parkinson's Disease Patient
Adaptive deep brain stimulation (DBS) devices aim to personalize stimulation delivery by following the current state of symptom-specific neural signals during different activities of daily living (walking, sleeping, etc.). This approach is not yet suitable for clinical practice, and groundwork is needed. The first essential steps for establishing adaptive DBS comprise the capacity for measurements in chronically implanted patients (to avoid the "stunning effect") 1 and for prolonged recordings not corrupted by artifacts. 2, 3 Our centers teamed up to address these challenges and were able to successfully record the bilateral subthalamic local field potentials for 24 hours in 1 patient chronically implanted for Parkinson's disease (ClinicalTrials.gov: NCT03422757). The recordings were performed in a 55-year-old woman suffering
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
from akinetic-rigid PD for 8 years and admitted to the hospital for battery replacement after 4 years of subthalamic DBS (Activa PC, lead model 3389; Medtronic). After 30-minute recordings (baseline) in stim-off/meds-off condition (overnight pausing of all dopaminergic medication), we set the new AlphaDBS device (Newronika Srl) 1 to the chronically active parameters (left: 3-C+, 4.8 V, 60 μs, 170 Hz; right: 11-C+, 5.5 V, 60 μs, 170 Hz). Recordings lasted for 24 hours continuously over 2 days, during which the patient freely performed everyday life activities and had approximately 6 hours of sleep at night. Recordings were performed during active stimulation in a differential configuration (left: contacts 0-1; right: contacts 8-9) and stored on the device. 1 We chose these contacts as they showed the highest peak in the β-frequency range. Despite active stimulation, we observed clear modulation of the low β-frequency range (13-20 Hz) following levodopa intake. 4 In this band, we recorded the highest interhemispheric subthalamic crossfrequency amplitude-amplitude coupling (r = 0.62, P < 0.0001) during the daytime, which diminished during night sleep (Fig. 1) . The clinical efficacy of DBS was maintained throughout the experiment, with stable improvement ranging between 30% and 37% (with respect to the baseline MDS-UPDRS part III score of 39/108), which was similar to that experienced by the patient at home (36% improvement in stim-on/meds-off at enrollment visit). During the study, the patient continued the home medication regimen and took 1 pill of fast-acting oral levodopa/benserazide 100/25 mg on 2 occasions. Levodopa improved parkinsonian symptoms by 5 points on the MDS-UPDRS part III score, without adverse events (i.e., dyskinesias). No adverse events or complaints by the patient were reported. The Ethical Committee approved the study, and all patients gave written informed consent.
Our results prove the feasibility of prolonged recordings (up to 24 hours) in freely moving, chronically stimulated patients. They further corroborate the hypothesis that oscillations in the β-frequency range might be used as a levodoparelated biomarker for adaptive DBS paradigms, as they are present during active stimulation and years after surgery. We also provide for the first time preliminary evidence that interhemispheric subthalamic coupling changes between wakefulness and sleep can be monitored and possibly serve as an additional behavior-specific biomarker. These findings pave the way for testing different adaptive stimulation paradigms for STN-DBS and prompt a more accurate definition of symptom-related and behavior-specific biomarkers in PD. 5 Mattia Arlotti, PhD, 1 Chiara Palmisano, Eng,
Minimal Clinically Important Difference for the Quality of Life in Essential Tremor Questionnaire
Essential tremor (ET) can considerably impair health-related quality of life (HRQoL). Disability and impairment, related to motor and nonmotor symptoms of the disease, can be specifically captured by the Quality of Life in Essential Tremor Questionnaire (QUEST).
1 Although this instrument is increasingly used in clinical practice and research, its minimal clinically important difference (MCID) has not yet been established. We therefore aimed to determine these threshold values that may provide guidance on judging the clinical relevance of changes associated with both disease progression and various treatment options.
A total of 248 consecutive patients with ET attending the Department of Neurology, Pécs, Hungary, between June 2013 and December 2018 were enrolled. In addition to demographic, medication, and disease-related data, the validated Hungarian version of the QUEST 2 was assessed at baseline. Disease severity was determined by the QUEST Summary Index (QUEST-SI) as mild (≤11.25), moderate (11.26-20.35), and severe (>20.35). 2 The major neurocognitive disorder was an exclusion criterion (Montreal Cognitive Assessment score <20.5). At follow-up visits, the QUEST-SI was reassessed, and patients rated the perceived changes in ET-related difficulties since the last visit on the Patient-rated Global Impression of Improvement (PGI-I) scale. The methods for calculating MCID were previously described in full detail elsewhere. 
